(Q30053056)

English

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

scientific article (publication date: November 2012)

In more languages

Statements

scholarly article

0 references

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial (English)

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2812%2961769-3

25 May 2017

phase III clinical trial

0 references

relapsing-remitting multiple sclerosis

0 references

multiple sclerosis

0 references

Hans-Peter Hartung

6

object named as

Hans-Peter Hartung

1 reference

DOI.org query endpoint

25 May 2017

Gavin Giovannoni

12

object named as

Gavin Giovannoni

1 reference

DOI.org query endpoint

25 May 2017

Howard L. Weiner

9

object named as

Howard L Weiner

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2812%2961769-3

25 May 2017

Ivana Kovářová

0 references

author name string

Jeffrey A Cohen

1

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2812%2961769-3

25 May 2017

Alasdair J Coles

2

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2812%2961769-3

25 May 2017

Douglas L Arnold

3

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2812%2961769-3

25 May 2017

Christian Confavreux

4

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2812%2961769-3

25 May 2017

Edward J Fox

5

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2812%2961769-3

25 May 2017

Eva Havrdova

7

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2812%2961769-3

25 May 2017

Krzysztof W Selmaj

8

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2812%2961769-3

25 May 2017

Elizabeth Fisher

10

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2812%2961769-3

25 May 2017

Vesna V Brinar

11

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2812%2961769-3

25 May 2017

Miroslav Stojanovic

13

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2812%2961769-3

25 May 2017

Bella I Ertik

14

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2812%2961769-3

25 May 2017

Stephen L Lake

15

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2812%2961769-3

25 May 2017

David H Margolin

16

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2812%2961769-3

25 May 2017

Michael A Panzara

17

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2812%2961769-3

25 May 2017

D Alastair S Compston

18

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2812%2961769-3

25 May 2017

language of work or name

0 references

publication date

November 2012

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2812%2961769-3

25 May 2017

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2812%2961769-3

25 May 2017

380

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2812%2961769-3

25 May 2017

9856

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2812%2961769-3

25 May 2017

1819-1828

1 reference

DOI.org query endpoint

https://doi.org/10.1016%2FS0140-6736%2812%2961769-3

25 May 2017

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Statistical methods for the analysis of relapse data in MS clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Two-Sample Asymptotically Distribution-Free Tests for Incomplete Multivariate Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicentre study of thyroid nodules in patients with Graves' disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Ultrasonographic screening for detection of thyroid cancer in patients with Graves' disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of incidental thyroid cancer and its ultrasonographic features in subcentimeter thyroid nodules of patients with hyperthyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Hashimoto's thyroiditis is not associated with increased risk of thyroid cancer in patients with thyroid nodules: a single-center prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961769-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30053056&oldid=1551397440"